An observational study in Late-Onset Neonatal Sepsis, Extreme Prematurity and Neonatal Hypotension, sponsored by Mount Sinai Hospital, Canada. Recruiting at 22 sites in 5 countries. Open to participants aged 21 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Mount Sinai Hospital, Canada · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.
Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.
Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.
Hypothesis: Primary treatment with NE will be associated with a lower mortality
Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:
Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response
Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
In this study, we will use real world data (RWD; defined as data generated during routine clinical practice) collected by our national Canadian Neonatal Network (CNN), which will be further expanded for this project.
The CNN is a well-established patient registry that includes members from 31 hospitals and 17 universities across Canada. The Network maintains a standardized NICU database and provides a unique opportunity for researchers to participate in collaborative projects. We will use the framework of Hypotheses Evaluating Treatment Effectiveness (HETE) research a form of comparative effectiveness research (CER).
Patient registries are emerging as a new method for assessment of treatments under the framework of CER. We will evaluate treatment effectiveness of two routinely used primary therapies for hypotension management in very preterm neonates with suspected LOS after standardizing treatment strategies and with a priori hypothesis.
193 studies on the registry are indexed under Neonatal Sepsis; 41 are open to participants now.
This study's planned enrollment of 550 is above the median of 200 across 85 observational studies indexed under Neonatal Sepsis.
Browse Neonatal Sepsis studies →Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All preterm infants born ≤32 weeks gestational age and > 48 hours of life with suspected sepsis with systemic hypotension admitted to the participating sites and meeting the above eligibility criteria will be included in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Units who have standardized their practice with the use of Dopamine as a first line agent.
Drug: Dopamine
Units who have standardized their practice with the use of Norepinephrine as a first line agent.
Drug: Norepinephrine
Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
All cause in-hospital mortality
Death before discharge
Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth
Episode-related death
Episode-related death (yes or no- binary variable)
Time frame: <14 days from illness onset
Treatment failure rate
Need for further dose escalation or use of additional agents (treatment failure = hypotension unresolved after reaching max dose (15mics/kg/min in Dopamine units and 0.15 mics/kg/min in Norepinephrine units)
Time frame: 90 minutes after initial vasopressor initiation (or sooner if secondary dose added or primary agent replaced as per clinical discretion)
New diagnosis of severe neurological injury
Grade III or Grade IV intraventricular hemorrhage or periventricular leukomalacia (yes or no- binary variable)
Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth
Bronchopulmonary dysplasia
Need for oxygen or positive pressure respiratory support at 36 weeks postmenstrual age (PMA) (yes or no- binary variable)
Time frame: Assessed at 36 weeks PMA
Retinopathy of prematurity
Diagnosis of retinopathy of prematurity - assessed by clinical staff (yes or no - binary variable)
Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth
Length of hospital stay
Length of entire neonatal intensive care unit stay from admission to discharge
Time frame: From admission date to discharge date - assessed up to a maximum of 36 weeks after date of birth
Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.
Of 37 non-industry observational studies under Neonatal Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 52 months is above that.
Counting every sponsor, half of 38 studies reached it within 28 months; a quarter within 16 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2026 → Jun 2027 and completion Mar 2027 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mount Sinai Hospital, Canada →